This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Juvenile Rheumatoid Arthritis연소성 류마티스관절염 (연소성류마티스관절염)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M08.0 | Special Copayment Reduction: V133 (rare disease)
B. SynonymsJuvenile rheumatoid arthritis with or without rheumatoid factor | Juvenile rheumatoid arthritis
C. Adult onsetLikelihood of first onset in adulthood low — by definition, juvenile rheumatoid arthritis (JRA/JIA) has onset before age 16. However, it is common for the disease to persist into adulthood in patients with childhood onset, and the RF-positive polyarticular type in particular transitions to adult rheumatoid arthritis or requires treatment into adulthood.
1. History

Juvenile Rheumatoid Arthritis (JRA) or juvenile idiopathic arthritis (Juvenile Idiopa…

2. Causes

The causes of the juvenile arthritis group of diseases are heterogeneous, and different immunologic mechanisms are involved depending on the disease subtype. In common, genetic…

3. Genetics

The juvenile arthritis group of diseases are complex genetic diseases, and the various genetic risk factors differ by subtype. The most important genetic risk factor is HL…

4. General epidemiology

Juvenile arthritis (JIA) is the most common chronic rheumatic disease of childhood. The prevalence of JIA overall (including all subtypes) is about 16–15… per 100,000 population

5. Pathophysiology

The pathophysiology of joint inflammation in juvenile arthritis differs by subtype. Common mechanisms include monocytes, macrophages, T cells and B cells within the synovium…

6. Symptoms

The main symptoms of juvenile arthritis are joint pain, swelling, stiffness and limited motion, with additional systemic symptoms depending on the subtype. Joint symptoms

7. Signs

On physical examination, joint swelling, warmth, limited range of motion and flexion contractures are the main signs. Longer morning stiffness reflects more severe inflammation. …

8. Screening

Screening for juvenile arthritis is performed in children with joint swelling or morning stiffness persisting for 6 weeks or longer. Basic screening tests include CBC, ESR, CRP,…

9. Diagnosis

The diagnosis of juvenile arthritis is made according to the 2001 revised International League of Associations for Rheumatology (ILAR) classification criteria. Core criteria: onset before age 16, 6 weeks or longer…

10. Treatment

The treatment goals for juvenile arthritis are complete suppression of joint inflammation (targeting remission, treat-to-target), prevention of joint damage and growth impairment, normal development and…

11. Prognosis

The long-term prognosis of juvenile arthritis differs greatly by subtype. In the RF-negative oligoarticular type, remission before adulthood can be achieved in about 50–60%, but with uveitis compli…

12. Prevention

Primary prevention of juvenile arthritis is impossible, but early diagnosis and treatment and prevention of complications are important. Regular ophthalmologic slit-lamp examination in ANA-positive oligoarticular patients…

13. References10 papers in major international journals.

1. History

Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) is an umbrella concept for chronic arthritis occurring in children younger than 16, with a long history and a complex development of classification. The earliest record is the description of chronic arthritis in children by Charles West of England in 1864, and in 1897 George Frederic Still described in detail chronic arthritis in children accompanied by systemic symptoms (fever, rash, lymphadenopathy), and it became known as 'Still disease'.

In the early-to-mid 20th century, childhood arthritis was regarded as a pediatric form of adult rheumatoid arthritis (RA), but immunologic research in the 1970s–80s confirmed that childhood arthritis is a heterogeneous group of diseases considerably different from RA both clinically and immunologically. In 1977, the American College of Rheumatology (ACR) proposed criteria classifying JRA (Juvenile Rheumatoid Arthritis) into 3 onset types (systemic, polyarticular, oligoarticular). In 1994, a European group separately established JCA (Juvenile Chronic Arthritis) criteria.

Subsequently, in 1997–2001, the International League of Associations for Rheumatology (ILAR) integrated these two classifications and proposed a new classification system called JIA (Juvenile Idiopathic Arthritis). The ILAR JIA classification consists of 7 subtypes (systemic, persistent oligoarticular, extended oligoarticular, RF-negative polyarticular, RF-positive polyarticular, psoriatic arthritis, enthesitis-related arthritis, undifferentiated). With the introduction of biologics (etanercept, abatacept, anakinra, tocilizumab, secukinumab, etc.), treatment of JIA has improved greatly since the 2000s.

2. Causes

The causes of the juvenile arthritis group of diseases are heterogeneous, and different immunologic mechanisms are involved depending on the disease subtype. In common, autoimmune or autoinflammatory mechanisms arising from the interaction of genetic predisposition and environmental triggers cause joint inflammation. Reported environmental triggers include viruses (parvovirus B19, rubella, CMV, EBV), bacteria (streptococci, Yersinia) and trauma, but a causal relationship between specific environmental factors and onset has mostly not been established.

In the RF-positive polyarticular type, rheumatoid factor (RF, IgM anti-IgG antibody) and anti-CCP (cyclic citrullinated peptide) antibodies cause joint destruction through autoimmune mechanisms similar to adult RA. In the systemic type (sJIA), as in AOSD, IL-1β-, IL-18- and IL-6-mediated autoinflammatory mechanisms are central. The oligoarticular and RF-negative polyarticular types are characterized by Th1/Th17-mediated intra-articular inflammatory responses and a risk of uveitis associated with ANA positivity. In enthesitis-related arthritis, spondyloarthropathy-type mechanisms associated with HLA-B27 (IL-17, IL-23 pathways) are involved.

3. Genetics

The juvenile arthritis group of diseases are complex genetic diseases, and the various genetic risk factors differ by subtype. The most important genetic risk factor is the HLA (Human Leukocyte Antigen) gene family. In the RF-positive polyarticular type, the HLA-DRB1*04 group (the same as in adult RA) is strongly associated. In the oligoarticular type, HLA-DRB1*01, *08, *11, DQA1*04 and DPB1*03 are associated. In enthesitis-related arthritis, HLA-B27 is a strong risk factor. In the systemic type, HLA associations are weak, and IL-6, IL-18 and NLRP3 polymorphisms have been reported.

As non-HLA risk genes, common autoimmunity genes such as PTPN22, CTLA4, STAT4 and IRF5 are associated with some JIA subtypes. In twin studies, the JIA concordance rate is lower than for monogenic inheritance, suggesting the importance of environmental factors. The significance of genetic counseling is relatively limited; there is a familial clustering risk (sibling relative risk about 15–20-fold), but the absolute risk is low.

4. General epidemiology

Juvenile arthritis (JIA) is the most common chronic rheumatic disease of childhood. The prevalence of JIA overall (including all subtypes) varies by study at about 16–150 per 100,000 population. In a Korean study using health insurance data, the annual incidence of JIA (M08) was estimated at about 5–10 per 100,000 population and the prevalence at about 25–50. The distribution by subtype varies with the study population, but the oligoarticular type is the most common (about 30–40%), the RF-negative polyarticular type second (about 25%) and the systemic type 10–15%. The age of onset differs by subtype, with an oligoarticular peak in girls aged 2–4 and an adolescent peak. Special Copayment Reduction V133 applies to all of juvenile rheumatoid arthritis (M08.0), juvenile ankylosing spondylitis (M08.1), systemic-onset type (M08.2) and juvenile polyarthritis (M08.3).

5. Pathophysiology

The pathophysiology of joint inflammation in juvenile arthritis differs by subtype. Common mechanisms include infiltration and activation of monocytes, macrophages, T cells and B cells within the synovium, proliferation and angiogenesis of fibroblast-like synoviocytes (FLS) and secretion of cartilage- and bone-destroying enzymes (RANKL, MMP, cathepsin). In the RF-positive polyarticular type, as in adult RA, anti-CCP antibody-mediated immune complexes induce complement activation in the joint, and ACPA (anti-CCP)-specific T cells sustain joint inflammation. In the systemic type, the pathway of NLRP3 inflammasome activation → excessive IL-1β and IL-18 secretion → macrophage activation (MAS risk) is central. In enthesitis-related arthritis, the IL-17/IL-23 axis and HLA-B27-related endoplasmic reticulum stress mechanisms cause enthesis inflammation. In the oligoarticular type, an imbalance of Th17 cells and regulatory T cells results in excessive IL-17 secretion within the joint.

6. Symptoms

The main symptoms of juvenile arthritis are joint pain, swelling, stiffness and limited motion, with additional systemic symptoms depending on the subtype. Joint symptoms: morning stiffness lasts 30 minutes or longer, and in children it uniquely presents as limping after waking (morning gait disturbance). Joint swelling, warmth and limited joint motion accompany it. In the oligoarticular type 4 or fewer joints are involved, and in the polyarticular type 5 or more. Symptoms specific to the systemic type (sJIA): as in AOSD, high fever (afternoon-to-evening spike pattern), salmon-colored rash, lymphadenopathy and hepatosplenomegaly are characteristic. Enthesitis-related arthritis: pain and swelling of the entheses (tendon insertion sites) appear along with arthritis of the large joints of the lower limbs. Ophthalmic complications: because asymptomatic anterior uveitis develops especially in the oligoarticular type and carries a risk of visual impairment, regular slit-lamp examination is essential.

In the RF-positive polyarticular type, rheumatoid nodules can rarely occur in children as well, reflecting the same pathogenesis as adult RA. The RF-negative oligoarticular type has the highest risk of uveitis complications, which can begin asymptomatically and lead to vision loss.

7. Signs

On physical examination, joint swelling, warmth, limited range of motion and flexion contractures are the main signs. Longer morning stiffness reflects more severe inflammation. In the systemic type, daily afternoon fever spikes and a salmon-colored rash (appearing with fever and disappearing with defervescence) are characteristic. When uveitis is present, slit-lamp examination confirms findings of anterior uveitis, and because it is initially asymptomatic, regular ophthalmologic examination for screening is needed. Growth impairment (local or generalized), leg length discrepancy and joint deformities may appear in children with long-standing involvement. Laboratory findings used for diagnosis include elevated ESR and CRP, thrombocytosis, anemia (anemia of chronic disease), RF (positive in the positive polyarticular type) and ANA (positive in about 50–60% of the oligoarticular type).

8. Screening

Screening for juvenile arthritis is performed in children with joint swelling or morning stiffness persisting for 6 weeks or longer. Basic screening tests include CBC, ESR, CRP, RF, ANA, liver and kidney function and uric acid. Because ANA-positive oligoarticular patients have a high risk of uveitis, they are referred immediately for pediatric ophthalmologic slit-lamp examination and screened regularly thereafter. HLA-B27 testing is performed when enthesitis-related arthritis or an ankylosing spondylitis variant is suspected. Anti-CCP antibody testing is used in RF-positive patients or patients with adolescent-onset polyarthritis to assess continuity with adult RA. Joint ultrasound is used to assess clinically unclear joint effusion and synovial thickening.

9. Diagnosis

The diagnosis of juvenile arthritis is made according to the 2001 revised International League of Associations for Rheumatology (ILAR) classification criteria. Core criteria: onset before age 16, arthritis of one or more joints persisting for 6 weeks or longer and exclusion of other causes. Subtype classification is based on the clinical features of the first 6 months of onset (number of joints, RF, ANA, HLA-B27, systemic symptoms). The differential diagnosis includes infectious arthritis (septic, viral), reactive arthritis, rheumatic fever, systemic lupus erythematosus (SLE), seronegative spondyloarthropathy and growing pains. Joint radiography (may be negative early), joint MRI (assessment of early synovial thickening and cartilage and bone damage) and joint ultrasound are used to support diagnosis.

10. Treatment

The treatment goals for juvenile arthritis are complete suppression of joint inflammation (targeting remission, treat-to-target), prevention of joint damage and growth impairment, and ensuring normal development and quality of life. NSAIDs: initial treatment of mild arthritis. Naproxen, ibuprofen, indomethacin. Intra-articular steroid injection: effective for target joints in the oligoarticular type. Triamcinolone hexacetonide preferred. Methotrexate (MTX): the basic DMARD for the polyarticular and extended oligoarticular types. Biologics: with an insufficient response to MTX, etanercept, abatacept, tocilizumab (systemic type), anakinra and canakinumab (systemic type, MAS), secukinumab (enthesitis-related arthritis). Specific to systemic JIA: IL-1 and IL-6 blockade is the first-line biologic treatment. Treatment of uveitis: topical steroids, MTX, adalimumab (TNF blockade). Physical therapy and rehabilitation are key to maintaining joint function.

11. Prognosis

The long-term prognosis of juvenile arthritis differs greatly by subtype. In the RF-negative oligoarticular type, remission before adulthood can be achieved in about 50–60%, but with uveitis complications there is a risk of visual impairment. The RF-positive polyarticular type often continues into adult RA, so its prognosis is relatively poor, and long-term maintenance of DMARDs and biologics is needed. The systemic type transitions to persistent chronic arthritis in about 1/3, and MAS carries mortality. Enthesitis-related arthritis can progress to ankylosing spondylitis in about 50%. Since the introduction of biologics, rates of remission and preservation of function have improved greatly. Management of transition to adulthood and a system for handover to adult rheumatologists are important.

12. Prevention

Primary prevention of juvenile arthritis is impossible, but early diagnosis and treatment and prevention of complications are important. In ANA-positive oligoarticular patients, regular ophthalmologic slit-lamp examination (every 4 months to 1 year after onset) detects and treats asymptomatic uveitis early. To prevent joint damage, early complete remission is targeted with a treat-to-target strategy. During immunosuppressive treatment, infections are prevented with vaccination (inactivated vaccines recommended, live vaccines contraindicated). Physical therapy, occupational therapy and sports rehabilitation maintain joint range of motion and muscle strength. Adjustments in school and social environments (education, accommodation in physical activities) are important for supporting the normal development of children.

13. References

  1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392. PMID: 14760812.
  2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. DOI: 10.1016/S0140-6736(07)60363-8. PMID: 17336654.
  3. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(4):465-482. DOI: 10.1002/acr.20459. PMID: 21452260.
  4. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202-1209. PMID: 9214419.
  5. Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290-2294. PMID: 15517650.
  6. Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin North Am. 2012;59(2):301-327. DOI: 10.1016/j.pcl.2012.03.014. PMID: 22560573.
  7. Klein A, Minden K, Hospach A, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(7):969-974. DOI: 10.1136/annrheumdis-2019-216579. PMID: 32350026.
  8. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658-666. DOI: 10.1002/art.24516. PMID: 19405003.
  9. Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(2):545-555. DOI: 10.1002/art.30128. PMID: 21280009.
  10. Horneff G, De Buck M, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(4):519-525. DOI: 10.1136/ard.2007.087593. PMID: 18445619.